Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have confirmed antibody-mediated Pure red cell aplasia (PRCA) are potentially eligible for enrollment into this study.~* Participants must be ≥ 18 years old at the time of consent.~* Erythropoiesis stimulating agents (ESAs) must be discontinued for a minimum of 1 month prior to screening.~* Participant requires periodic transfusions to maintain hemoglobin.~* Hemoglobin \< 10 g/dL for at least 2 measurements or participant has received a transfusion within the past 4 weeks to achieve a hemoglobin \> 10 g/dL.~* Confirmation that an anti-erythropoietin antibody sample was obtained for analysis by the central reference laboratory within 1 month prior to baseline.~* Participants can either be participants with chronic kidney disease not yet requiring renal replacement therapy (participants not on dialysis), those on regular hemodialysis or peritoneal dialysis, or following a renal transplant.~* Participants may or may not have previously been treated with immunosuppressive therapy.~* Pre-menopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening.~* Written informed consent must be obtained.~Exclusion Criteria:~* Participants already successfully on another erythropoietic agent.~* Abnormal bone marrow findings consistent with the diagnosis of myelodysplasia, a myeloproliferative disorder, hematologic malignancy or evidence of metastatic infiltration.~* Poorly controlled hypertension.~* Previous exposure to any investigational agent within 4 weeks prior to administration of study drug or planned receipt during the study period.~* High likelihood of early withdrawal or interruption of the study.~* Participants who refuse to give informed consent.~* Women who are pregnant, lactating or not using a medically approved birth control.~* Life expectancy \<12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginesatide (Type: EXPERIMENTAL): Peginesatide 0.05 mg/kg injection, subcutaneously as a starting dose followed by peginesatide 0.1 mg/kg injection, subcutaneously once every 4 weeks for up to 6 months.~Individual dose of peginesatide injection was modified based on hemoglobin levels. Dose adjustments were made in order to achieve and maintain hemoglobin in the target range of 10.0-12.0 g/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).